Strata Skin Sciences

SSKN

Market cap $10.7M

First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to address the condition

HORSHAM, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- In recognition of Eczema Awareness Month, STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, highlights the substantial body of peer-reviewed clinical evidence supporting the XTRAC® Excimer Laser (308 nm) as a safe, highly effective treatment for localized atopic dermatitis, the most common form of eczema. This recognition comes as the American Medical Association (AMA) has expanded excimer laser's indications to inflammatory and autoimmune skin diseases, clearing the way for Medicare, Medicaid, and private payer reimbursement for atopic dermatitis treatment.

HORSHAM, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a new peer-reviewed study in Lasers in Medical Science that reinforces the Company's commitment to personalized medicine. The study demonstrates that treatment using the Company's XTRAC 308nm Excimer Laser in combination with 0.1% tacrolimus ointment significantly improves outcomes in patients with plaque-type psoriasis compared to topical monotherapy.

Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and expanding indications Investigator-initiated randomized controlled combination trial published in the International Journal of Dermatology confirms its superiority to monotherapy, fueling continued market growth and expanding indications

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company's common stock at a per share purchase price of $2.204.

Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention Consulting program optimizes partner clinic businesses with implementation of best practices initiatives, including marketing, reimbursement, and patient retention

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Dolev Rafaeli - President, CEO & Vice-Chairman John Gillings - Principal Financial Officer & Chief Accounting Officer Conference Call Participants Jeffrey Scott Cohen - Ladenburg Thalmann & Co. Inc., Research Division Jeremy Pearlman - Maxim Group LLC, Research Division Jules Abraham - CorProminence, LLC Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the STRATA Skin Sciences Inc. Second Quarter 2025 Financial Results and Corporate Update Conference Call.

Peer-reviewed publications continue to validate Excimer Laser efficacy in vitiligo and treatment STRATA updates status of non-Excimer laser false advertising litigation HORSHAM, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced it is working with the Centers for Medicare & Medicaid Services (CMS) to obtain temporary codes that would accelerate access to recently expanded reimbursement for its XTRAC® excimer laser treatment.

HORSHAM, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 after the market close.

STRATA Skin Sciences, Inc. (NASDAQ:SSKN ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Jules Abraham - CORE IR Dolev Rafaeli - Chief Executive Officer John Gillings - VP of Finance Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Jeremy Pearlman - Maxim Group Operator Good afternoon, and welcome to the STRATA Skin Sciences First Quarter 2025 Financial Results Conference Call. All participants will be in a listen-only mode.